Research-use catalog page
COA request, lot visibility, availability, and schema stay aligned.
CJC-1295 With DAC is a long-acting GHRH analog with albumin-binding modification that sustains elevated GH and IGF-1 for 6–8 days per administration in preclinical and early clinical research.
Temporarily unavailable
This product is listed in the catalog, but it is not currently available for ordering. Pricing, specifications, and support details remain visible while launch availability is being finalized.
Free shipping on orders over $150
Research Supplies
Need bacteriostatic water, syringes, or an alcohol prep kit? Email us — we can bundle reconstitution supplies with your order.
Ask about a research kit →Need the COA before you order? Request it here.
In your order
Lyophilized vial
Sterile-filtered, freeze-dried peptide in glass vial, sealed under inert gas.
Lot ID on every vial
Printed lot ID ties this exact vial to its analytical record.
COA on request
Independent third-party HPLC certificate, matched to your lot, sent on request.
Carrier-tracked shipping
Shipped from a US facility with full carrier tracking and protective packaging.
The Peptific standard
Peptide quality is invisible until it isn’t. Lot identity, purity, fill integrity, and chain of custody are the difference between usable research material and wasted budget.
Third-party HPLC tested
Every lot is tested for identity and purity by an independent analytical lab. Certificate of Analysis available on request, tied to the exact lot you receive.
Lyophilized and lot-tracked
Sterile-filtered, freeze-dried, sealed under inert gas. Each vial carries its own lot ID — full chain of custody from fill to delivery.
US-based fulfillment
Orders ship from a temperature-controlled US facility with carrier tracking. No drop-shipping, no opaque overseas relay.
Real support, not a ticket queue
A real person responds to research questions, lot questions, and order questions — usually same business day. No bot triage.
How it works
CJC-1295 With DAC stimulates GH secretion by binding and activating GHRH receptors on pituitary somatotropes. The Drug Affinity Complex (DAC) modification enables covalent albumin binding in vivo, extending the half-life from minutes (native GHRH) to approximately 6–8 days. Preclinical and Phase I human data show dose-dependent GH and IGF-1 elevation following single administration.
Compound profile
Product definition
CJC-1295 With DAC is a long-acting GHRH analog with albumin-binding modification that sustains elevated GH and IGF-1 for 6–8 days per administration in preclinical and early clinical research.
CJC-1295 With DAC (also known as DAC:GRF) is a synthetic GHRH analog with a maleimide-modified lysine residue that forms a covalent bond with serum albumin following administration. This albumin-binding mechanism — the Drug Affinity Complex (DAC) technology — dramatically extends plasma half-life and produces a sustained pulsatile GH secretion pattern over approximately one week per dose. The compound was investigated in Phase I/II clinical studies by ConjuChem Inc., where it demonstrated dose-dependent GH and IGF-1 elevation with a half-life of approximately 6–8 days in human volunteers. The research profile documents its utility in sustained GH axis stimulation, with potential applications in body composition research, metabolic studies, and investigations of GH-dependent anabolic signaling pathways.
Research audience
CJC-1295 With DAC is used by researchers studying the growth hormone axis, GHRH receptor pharmacology, sustained GH secretion protocols, GH-dependent metabolic signaling, and body composition mechanisms. It is particularly valuable in protocols requiring sustained GH elevation without frequent compound administration.
Research context
CJC-1295 With DAC was developed by ConjuChem using their Drug Affinity Complex technology, which was designed to extend the half-life of peptide therapeutics through in-vivo albumin binding. The compound was taken through Phase I and early Phase II human trials before development was discontinued for commercial reasons unrelated to safety or efficacy signals. The published pharmacokinetic data from these studies represents the most rigorous human-subject characterization of a long-acting GHRH analog in the open literature. Dose-dependent GH and IGF-1 responses were confirmed across multiple dose cohorts, with a mean half-life of 6–8 days and GH AUC increases ranging from approximately 2-fold at low doses to 10-fold at higher doses. In preclinical research, CJC-1295 With DAC has been studied in contexts including muscle mass preservation, GH-dependent metabolic effects, and GH axis modulation in aging models. The compound remains a reference standard in GH secretagogue research due to the availability of published pharmacokinetic data.
Common questions
Research Use Only
Sold for laboratory and research purposes only. Not approved for, nor intended for, human or veterinary consumption, diagnostic use, or therapeutic application. These products have not been evaluated by the Food and Drug Administration. Keep out of reach of children. For use by qualified researchers only.
Nothing on this page constitutes medical advice, a treatment recommendation, or a clinical protocol. Consult a qualified healthcare provider before making any health or treatment decisions.
By accessing this product page you confirm that you are a qualified researcher aged 18 or older and that you will use this product solely for lawful laboratory research purposes. View Research Use Policy
You might also want to check out these products.
2X Blend CJC-1295 Without DAC / Ipamorelin
The 2X Blend combines CJC-1295 Without DAC and Ipamorelin — the standard GHRH+GHRP research combination producing synergistic, selective GH pulse amplification through two independent receptor systems.
CJC-1295 Without DAC
CJC-1295 Without DAC (MOD GRF 1-29) is a tetrasubstituted GHRH(1-29) analog with ~30-minute half-life — the preferred short-acting GHRH analog for pulsatile GH research protocols, commonly paired with ipamorelin.
GHRP-6 Acetate
GHRP-6 is a hexapeptide GHS-R1a agonist and the founding GHRP compound — studied in preclinical models for GH release, significant appetite stimulation, and cortisol co-stimulation via ghrelin receptor activation.
Ipamorelin
Ipamorelin is a selective pentapeptide GHRP studied in preclinical models for GH release without cortisol or prolactin elevation — the most selective GHRP in its class.
IGF-1LR3
IGF-1 LR3 is an 83-amino-acid IGF-1 analog with reduced IGFBP binding, extending half-life from ~15 minutes to ~20–30 hours — the most studied long-acting IGF-1 analog in preclinical research.
Hexarelin Acetate
Hexarelin (Examorelin) is the most potent characterized GHRP hexapeptide — GHS-R1a agonist with Phase II human data and unique CD36 cardiac receptor binding providing GH-independent cardioprotection in animal models.
IGF-DES
Tesamorelin
Tesamorelin is a 44-amino-acid GHRH analog with N-terminal trans-3-hexenoic acid modification — the only FDA-approved GHRH peptide, validated in Phase III trials for visceral adiposity reduction.
Sermorelin
Sermorelin is a 29-amino-acid synthetic GHRH(1-29) analog — the first FDA-approved GHRH peptide (Geref), with the longest published research history of any synthetic GHRH compound.
MOD GRF 1-29
MOD GRF 1-29 (CJC-1295 Without DAC) is a tetrasubstituted GHRH(1-29) analog with ~30-minute half-life — the most commonly used short-acting GHRH compound for pulsatile GH secretion research.
GHRP-2
GHRP-2 (Pralmorelin) is a synthetic hexapeptide GHS-R1a agonist approved in Japan for GH stimulation testing — a potent non-selective GHRP that stimulates GH alongside cortisol and prolactin.
$12.00
$30.00
$29.00